An Early Phase 1 interventional study of EXG001-307 injection in Spinal Muscular Atrophy (SMA), sponsored by Hangzhou Jiayin Biotech Ltd. Enrolling by invitation at 2 sites in China. Open to participants aged 1 Day to 2 Years. Per ClinicalTrials.gov, last updated 2025-03-21.
Sponsored by Hangzhou Jiayin Biotech Ltd · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Muscular Atrophy, Spinal with a site in China — 6 open to participants now, 13 under way, 4 of them phase 3. Muscular Atrophy, Spinal · China.
Among the 23 studies in Muscular Atrophy, Spinal with a site in China, this one is the 16th largest by planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2025, is the only one in phase 1, reaches primary completion later than 0 of the 12 other live ones, and was the 18th registered.
282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.
Browse Muscular Atrophy, Spinal studies →6 of the 23 studies in Muscular Atrophy, Spinal with a site in China are open now. Recruiting first, the newest first:
Biogen · Sites in China, United States, Brazil and 2 more countries
Ages 15–60
Biogen · Sites in China, United States, Australia and 4 more countries
Ages 0 days–42 days
GeneCradle Inc · Sites in China
Ages 0 mo–6 mo
Wan-Jin Chen · Sites in China
Ages 1 wk–70 yrs · Healthy volunteers
Hangzhou Jiayin Biotech Ltd · Sites in China
Ages 1 mo+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.
This study: 1 Day to 2 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 7
First in 2016; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 4 is below the median of 29 across 156 interventional studies indexed under Muscular Atrophy, Spinal.
Median enrollment 35 across the 16 interventional studies, 200 across the 7 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 23 have an industry lead sponsor. The 10 most frequent:
Hangzhou Jiayin Biotech Ltd is the lead sponsor of 7 studies on the registry; 6 are open to participants now.
Hangzhou Jiayin Biotech Ltd has 2 studies filed under Muscular Atrophy, Spinal — fewer than ten, so there is no comparison to draw.
5 of the studies in Muscular Atrophy, Spinal with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06971094Phase 3GeneCradle IncSafety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III | 2026-12-31 |
| NCT05824169GeneCradle IncEvaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients | 2026-12 |
| NCT07822711Peking University Third HospitalEffects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA | 2027-01-15 |
| NCT05042921BiogenPediatric Spinal Muscular Atrophy (SMA) China Registry | 2027-09-02 |
| NCT06288230Lantu BiopharmaAn Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 23 studies in Muscular Atrophy, Spinal with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to evaluate safety and efficacy of intrathecal delivery of EXG001-307 as a treatment of spinal muscular atrophy .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
4.The subject's legal guardian understands the purpose, possible risks and interests of the study, agrees to participate in the study, completes all study procedures, tests and visits, and voluntarily signs the form.
5.During the study, the subject's legal guardian was willing to perform standard treatment requirements such as nasogastric feeding, noninvasive mechanical ventilation, and expectoration machine as recommended by the investigator.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose 1 Intrathecal administration dose 1 of EXG001-307 to SMA patient (type I \&type II)
Biological: EXG001-307 injection
non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.
To evaluate the safety and tolerability of EXG001-307 following a single intrathecal injection
Adverse events (AES), serious adverse events (SAEs), dose-limited toxicity types, severity, incidence, and drug relevance were evaluated after treatment.(Evaluate through examinations such as electrocardiogram, echocardiography, blood routine, blood biochemistry, coagulation function, etc. conducted during each visit)
Time frame: up to 52 weeks after treatment
Evaluate the improvement of motor function in subjects after treatment: assessed with the BSID-III scale
The achievement of new milestones in the BSID-III
Time frame: up to 52 weeks after treatment
Evaluate the improvement of motor function in subjects after treatment: assessed with the CHOP-INTEND scale
Evaluate the changes in subjects' scores compared to baseline and the proportion of subjects with scores above 40 using the CHOP-INTEND scale.
Time frame: up to 52 weeks after treatment
Evaluate the improvement of motor function in subjects after treatment: assessed with the HINE-2 scale
Evaluate the achievement of motor milestones by the Hammersmith Infant Neurological Examination (HINE-2) Module 2
Time frame: up to 52 weeks after treatment
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2025; primary completion for Mar 2026, 12 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hangzhou Jiayin Biotech Ltd